{
    "2018-12-03": [
        [
            {
                "time": "2018-12-03",
                "original_text": "Cramer Remix: These recession-proof stocks are worth buying on a pullback",
                "features": {
                    "keywords": [
                        "recession-proof",
                        "stocks",
                        "pullback"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-12-03",
                "original_text": "Health Care Sector Update for 12/03/2018: ARGX,GBT,GSK,TSRO,AGIO",
                "features": {
                    "keywords": [
                        "Health Care",
                        "Sector Update",
                        "ARGX",
                        "GBT",
                        "GSK",
                        "TSRO",
                        "AGIO"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "health care"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-03",
                "original_text": "Health Care Sector Update for 12/03/2018: TSRO, GSK, VNDA, GBT, JNJ, PFE, ABT, MRK, AMGN",
                "features": {
                    "keywords": [
                        "Health Care",
                        "Sector Update",
                        "TSRO",
                        "GSK",
                        "VNDA",
                        "GBT",
                        "JNJ",
                        "PFE",
                        "ABT",
                        "MRK",
                        "AMGN"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "health care"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-03",
                "original_text": "Dutch firm argenx, J&J affiliate to collaborate on cancer therapy",
                "features": {
                    "keywords": [
                        "Dutch firm",
                        "argenx",
                        "J&J",
                        "cancer therapy",
                        "collaborate"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "health care"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-12-03",
                "original_text": "J&J to Build Blood-Cancer Push With Controversial China Biotech",
                "features": {
                    "keywords": [
                        "J&J",
                        "Blood-Cancer",
                        "Controversial",
                        "China Biotech"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "health care"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}